MBC Pharma (United States)

Recent papers from MBC Pharma (United States)

1. Understanding patterns of behavioral health referrals for chronic disease in integrated care settings.2026
2. Patient and Care Team Perspectives of Barriers to and Facilitators for the Implementation of a Digital Health Program for Depression in Primary Care: Qualitative StudyJournal of Medical Internet Research · 2026
3. A Highly Protective Clade 1 and 2 Cross-Reactive Pandemic Influenza Virus Vaccine Based on a 4th Generation Fully Deleted Adenoviral Vector of a Rare Serotype2025
4. Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and DogsMolecules · 2025
5. Protecting Allogeneic Pancreatic Islet Grafts by Engineered Veto2024
6. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy ParticipantsClinical Pharmacology in Drug Development · 2020
7. The promise of Immuno-oncology: implications for defining the value of cancer treatmentJournal for ImmunoTherapy of Cancer · 2019
8. Global vaccinology training: Report from an ADVAC workshopVaccine · 2019
9. Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy VolunteersClinical Pharmacology in Drug Development · 2018
10. 3D electron tomographic and biochemical analysis of ER, Golgi and trans Golgi network membrane systems in stimulated Venus flytrap (Dionaea muscipula) glandular cellsJournal of Biological Research - Thessaloniki · 2018
11. Bisphosphonate conjugation for bone specific drug targetingBone Reports · 2018
12. StrandAdvantage test for early‐line and advanced‐stage treatment decisions in solid tumorsCancer Medicine · 2017
13. Effect of helix length on the stability of the lac repressor antiparallel coiled coilBiopolymers · 2015
14. Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy SubjectsBlood · 2014
15. Bisphosphonate Derivatives of Nucleoside Antimetabolites: Hydrolytic Stability and Hydroxyapatite Adsorption of 5′-β,γ-Methylene and 5′-β,γ-(1-Hydroxyethylidene) Triphosphates of 5-Fluorouridine and ara-CytidineThe Journal of Organic Chemistry · 2008
16. Symptomatic Reversal of Peripheral Neuropathy in Patients with DiabetesJournal of the American Podiatric Medical Association · 2002